<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport Launching Logistics Study for Bioanalytical and Clinical Trial Materials

August 30, 2016

Cryoport launched a study examining the effects of temperature and transport packaging on biomarkers and cell-therapy cancer vaccines. Currently, little research has examined shipping conditions’ effect on sample integrity. The study results will help educate clients and ensure that the most optimal shipping conditions are used when transporting materials for clinical trials. Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, explains the impact in an interview with Outsourcing Pharma. Read more >

CenterWatch Interview: Cryoport’s Chief Commercial Officer, Mark W. Sawicki, Ph.D., on a New Era of Logistics Challenges

August 22, 2016

Logistics, and particularly cold chain logistics, has taken an increasingly important role in the development of new therapeutics. With the advent of regenerative medicines and personalized therapies, many advanced cell and gene therapies are extremely sensitive to temperature. Companies that may have once approached logistics as an afterthought are formulating detailed logistics plans factoring in temperature control, time and detailed point-to-point monitoring. In an interview with CenterWatch, Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, describes the challenges and solutions of cryogenic transport in a new age of therapeutic development. Read more >

Cryoport to Convert Life Science Shipping Logistics For Contract Manufacturer

August 06, 2016

Cryoport continues to grow with the recent signing of an agreement with a leading contract biopharmaceutical supplier to convert its current fleet of liquid nitrogen (LN2) dewars to Cryoport’s comprehensive shipping solution. The client will use Cryoport Express® shippers and Cryoport’s advanced SmartPak II™ condition monitoring system for its contract manufacturing biologics and cell therapy businesses. Read more >

Supply Chain Challenges with New Therapies

July 07, 2016

Supply chains for many regenerative therapies can be very complex. Where traditional pharmaceuticals have linear supply chain models, autologous cell therapies oftentimes require circular supply chains, with little room for error. Tamie Joeckel, senior vice president, client services and consulting, discusses comprehensive strategies used to mitigate risk and manage cold chain complexities. Read more >


The Best Chance of Delivery for Life-Giving Shipments

June 21, 2016

As Asia’s pharmaceutical and biopharmaceutical industries grow, the infrastructure, supply chain management and logistics management challenges necessitate innovation. The need for proper shipping practices, including deep frozen and temperature-controlled logistics, will increase and continue to drive demand for these services. Cryoport’s innovative cold chain services and technologies meet the demands of the operational and regulatory complexities of the region. 
Read more >


Cryogenic Gas Solutions Drive Regenerative Therapies in Life Sciences

June 06, 2016

Innovation in the pharmaceutical industry is being led by regenerative therapies. Many of these new therapies need to be maintained at cryogenic conditions during storage and transport and cannot be supported by traditional shipping solutions. In this article, Tamie Joeckel, senior vice president, client services and consulting, explains how Cryoport’s shipping solutions support breakthrough treatments with technology as innovative as the treatments themselves. Read more >


Logistical Nightmare

May 10, 2016

Today’s most innovative medical breakthroughs, including cell therapies, tissue engineering, gene-modified cell therapies and genome editing therapies have three things in common: They are complicated, very expensive to produce and extremely temperature-sensitive. In this informative article published in Pharmaceutical Manufacturing and Packing Sourcer (PMPS), Cryoport Chief Commercial Officer Mark Sawicki, Ph.D., examines logistics planning and risk mitigation as they pertain to clinical trials; the impact of cold chain transportation on data integrity; and the regulatory landscape. Read more >

Consequences of Using Non-Frozen Delivery Systems Putting Biopharmaceutical Cargo at Risk

May 09, 2016

Non-frozen delivery systems for new drug therapies do not always provide acceptable temperature control. In the event of a transportation delay, medicines that require strict temperature management can be compromised. For these reasons, current packing configurations are being reevaluated in terms of the risks they pose to product integrity.

In this informative article published in Industry Today, Mark Sawicki, Ph.D., Cryoport chief commercial officer, describes how regulatory groups, such as ISO, are reviewing guidelines for the storage and distribution of regenerative therapies and other critical shipments. Read more >


Inside the Hidden Global Supply Chain for Frozen Sperm, Eggs and Embryos

April 25, 2016

Having a baby through IVF can be a global endeavor. With the eggs, sperm and surrogate each potentially coming from a different country, the role of the cold chain has never been more important. Cryoport was featured in a Wired article highlighting the specialized dewar and monitoring technology that goes into safely transporting frozen IVF materials around the world. Read more >


Cold Chain: Going the Extra Mile

February 01, 2016

Changing global regulatory requirements and complex supply chains have resulted in increasingly conservative approaches to temperature control in biopharmaceutical logistics. Cryoport Chief Commercial Officer Mark Sawicki, Ph.D., discusses the importance of risk management and condition monitoring systems for maintaining material and data integrity when shipping temperature-sensitive pharmaceuticals. Read more >